Login / Signup

Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials.

Marta Mascarenas-GarciaAlejandro Rivero-de-AguilarMónica Pérez-RíosAlberto Ruano-RaviñaMiguel Angel Llaneza-GonzalezCristina Candal-PedreiraJulia Rey-BrandarizLeonor Varela-Lema
Published in: Journal of neurology, neurosurgery, and psychiatry (2023)
RCTs for DMTs in MS have relevant and frequent limitations. These should be addressed to enhance their quality, transparency and external validity.
Keyphrases
  • phase iii
  • multiple sclerosis
  • clinical trial
  • open label
  • phase ii
  • double blind
  • primary care
  • healthcare
  • mass spectrometry
  • white matter
  • placebo controlled
  • ms ms
  • systematic review
  • data analysis